Timothy Hughes
Affiliations: | University of Oslo, Norway, Oslo, Oslo, Norway |
Website:
http://ous-research.no/hughes/Google:
"Timothy Hughes"
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Hochhaus A, Baccarani M, Silver RT, et al. (2020) European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia |
| Akkouh IA, Skrede S, Holmgren A, et al. (2019) Exploring lithium's transcriptional mechanisms of action in bipolar disorder: a multi-step study. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology |
| Hiwase D, Tan P, D'Rozario J, et al. (2018) Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift study. Leukemia Research. 67: 109-115 |
| Nicolini FE, Basak GW, Kim DW, et al. (2017) Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation. Cancer |
| Sopper S, Mustjoki S, White D, et al. (2017) Reduced CD62L Expression on T Cells and Increased Soluble CD62L Levels Predict Molecular Response to Tyrosine Kinase Inhibitor Therapy in Early Chronic-Phase Chronic Myelogenous Leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 35: 175-184 |
| Banjar H, Ranasinghe D, Brown F, et al. (2017) Modelling Predictors of Molecular Response to Frontline Imatinib for Patients with Chronic Myeloid Leukaemia. Plos One. 12: e0168947 |
| Radich J, Mahon F, Hochhaus A, et al. (2017) ENESTfreedom and ENESTop Update: Durable Treatment-Free Remission (TFR) at 96 Weeks after Nilotinib Treatment Cessation in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Clinical Lymphoma Myeloma and Leukemia. 17: S314-S315 |
| Lipton JH, Chuah C, Guerci-Bresler A, et al. (2016) Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. The Lancet. Oncology |
| Mahon F, Hochhaus A, Hughes T, et al. (2016) Treatment-Free Remission (TFR) Following Frontline or Second-Line Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENESTfreedom and ENESTop Clinical Lymphoma Myeloma and Leukemia. 16: S64-S65 |
| Olshen A, Tang M, Cortes J, et al. (2014) Dynamics of chronic myeloid leukemia response to dasatinib, nilotinib, and high-dose imatinib. Haematologica. 99: 1701-9 |